OMIC
Singular Genomics Systems, Inc. [OMIC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OMIC Stock Summary
Top 10 Correlated ETFs
OMIC
Top 10 Correlated Stocks
OMIC
In the News
Singular Genomics Systems, Inc. (OMIC) Q4 2022 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Drew Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Matt Sykes - Goldman Sachs Daniel Brennan - Cowen & Co. Operator Greetings, and welcome to the Singular Genomics Systems, Incorporated Fourth Quarter 2022 Earnings Conference Call.[Operator Instructions] Please note, this conference is being recorded.
Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 21.62% and 27.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Singular Genomics to Report Fourth Quarter 2022 Financial Results on March 2, 2023
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, March 2, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics: Betting On Expanding Genomics Systems Market
Singular Genomics Systems is a unique opportunity to invest in a commercially-viable startup at the forefront of a rapidly expanding field. The company has adequate funding to maintain its current level of commercialization and sales activity for a few years.
Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Singular Genomics Systems, Inc. (OMIC) Q3 2022 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Bruce Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tom Stevens - Cowen John Sourbeer - UBS Operator Good day, ladies and gentlemen and welcome to the Singular Genomics Systems, Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor, Investor Relations for Singular Genomics.
Singular Genomics to Report Third Quarter 2022 Financial Results on November 7, 2022
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
Singular Genomics Systems, Inc. (OMIC) CEO Drew Spaventa on Q2 2022 Results - Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder & CEO Dalen Meeter - Head, Finance Eli Glezer - Founder and Chief Scientific Officer Conference Call Participants Dan Brennan - Cowen Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Good day, ladies and gentlemen, and welcome to the Singular Genomics Systems, Incorporated Second Quarter 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for questions and comments after the presentation.
Singular Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California.
OMIC Financial details
OMIC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0.01 | |
| Net income per share | -0.25 | -0.57 | -1.38 | -1.28 | |
| Operating cash flow per share | -0.23 | -0.5 | 0 | -1.22 | |
| Free cash flow per share | -0.25 | -0.53 | 0 | -1.31 | |
| Cash per share | 0.94 | 0.54 | 4.73 | 3.44 | |
| Book value per share | -0.5 | -1.04 | 4.69 | 3.66 | |
| Tangible book value per share | -0.5 | -1.04 | 4.69 | 3.66 | |
| Share holders equity per share | -0.5 | -1.04 | 4.69 | 3.66 | |
| Interest debt per share | 0.05 | 0.2 | 0.01 | 0.84 | |
| Market cap | 1.27B | 1.27B | 829.1M | 143.01M | |
| Enterprise value | 1.27B | 1.27B | 637.96M | 127.59M | |
| P/E ratio | -103.1 | -45.47 | -8.39 | -1.57 | |
| Price to sales ratio | 0 | 0 | 0 | 186.94 | |
| POCF ratio | -111.47 | -51.08 | 0 | -1.64 | |
| PFCF ratio | -104.16 | -48.4 | 0 | -1.54 | |
| P/B Ratio | -51.39 | -24.65 | 2.47 | 0.55 | |
| PTB ratio | -51.39 | -24.65 | 2.47 | 0.55 | |
| EV to sales | 0 | 0 | 0 | 166.78 | |
| Enterprise value over EBITDA | -106.01 | -47.7 | -6.51 | -1.52 | |
| EV to operating cash flow | -111.2 | -50.99 | 0 | -1.46 | |
| EV to free cash flow | -103.9 | -48.31 | 0 | -1.37 | |
| Earnings yield | -0.01 | -0.02 | -0.12 | -0.64 | |
| Free cash flow yield | -0.01 | -0.02 | 0 | -0.65 | |
| Debt to equity | -2.95 | -1.59 | 0.06 | 0.26 | |
| Debt to assets | 1.51 | 2.69 | 0.05 | 0.21 | |
| Net debt to EBITDA | 0.26 | 0.09 | 1.95 | 0.18 | |
| Current ratio | 41.78 | 7.47 | 51.57 | 19.01 | |
| Interest coverage | -751.18 | -38.35 | -72.43 | -122.53 | |
| Income quality | 0.92 | 0.89 | 0 | 0.96 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 60.39 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.07 | 0.06 | 0 | 0.07 | |
| Capex to revenue | 0 | 0 | 0 | -7.87 | |
| Capex to depreciation | -2.29 | -2.16 | 0 | -1 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 17.87 | |
| Graham number | 1.68 | 3.64 | 12.05 | 10.25 | |
| ROIC | -0.35 | -4.11 | 0 | -0.53 | |
| Return on tangible assets | -0.26 | -0.92 | -0.28 | -0.28 | |
| Graham Net | -0.54 | -1.12 | 4.46 | 2.62 | |
| Working capital | 45.35M | 23.88M | 341.02M | 254.31M | |
| Tangible asset value | -24.73M | -51.56M | 336.17M | 260.32M | |
| Net current asset value | -26.44M | -54.49M | 328.29M | 200.78M | |
| Invested capital | -0.1 | -0.18 | 0 | 0.23 | |
| Average receivables | 0 | 0 | 0 | 456.5K | |
| Average payables | 0 | 494K | 1.39M | 2.72M | |
| Average inventory | 0 | 0 | 0 | 9.11M | |
| Days sales outstanding | 0 | 0 | 0 | 435.61 | |
| Days payables outstanding | 0 | 0 | 0 | 1.43K | |
| Days of inventory on hand | 0 | 0 | 0 | 8.43K | |
| Receivables turnover | 0 | 0 | 0 | 0.84 | |
| Payables turnover | 0 | 0 | 0 | 0.25 | |
| Inventory turnover | 0 | 0 | 0 | 0.04 | |
| ROE | 0.5 | 0.54 | -0.29 | -0.35 | |
| Capex per share | -0.02 | -0.03 | 0 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
| Net income per share | -0.25 | -0.27 | -0.31 | -0.33 | -0.3 | |
| Operating cash flow per share | -0.15 | 0 | -0.28 | -0.31 | -0.28 | |
| Free cash flow per share | -0.18 | 0 | -0.29 | -0.32 | -0.31 | |
| Cash per share | 4.98 | 4.7 | 4.45 | 3.7 | 3.44 | |
| Book value per share | 4.91 | 4.66 | 4.47 | 3.89 | 3.66 | |
| Tangible book value per share | 4.91 | 4.66 | 4.47 | 3.89 | 3.66 | |
| Share holders equity per share | 4.91 | 4.66 | 4.47 | 3.89 | 3.66 | |
| Interest debt per share | 0.14 | 0.14 | 0.23 | 0.83 | 0.83 | |
| Market cap | 802.57M | 834.2M | 448.08M | 178.04M | 143.01M | |
| Enterprise value | 573.17M | 643.06M | 275.97M | 143.83M | 127.59M | |
| P/E ratio | -11.39 | -10.55 | -5.09 | -1.87 | -1.69 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 186.94 | |
| POCF ratio | -73.12 | 0 | -22.59 | -8.17 | -7.18 | |
| PFCF ratio | -63.71 | 0 | -21.57 | -7.77 | -6.58 | |
| P/B Ratio | 2.28 | 2.48 | 1.41 | 0.64 | 0.55 | |
| PTB ratio | 2.28 | 2.48 | 1.41 | 0.64 | 0.55 | |
| EV to sales | 0 | 0 | 0 | 0 | 166.78 | |
| Enterprise value over EBITDA | -33.57 | -32.86 | -13.29 | -6.56 | -6.67 | |
| EV to operating cash flow | -52.22 | 0 | -13.91 | -6.6 | -6.41 | |
| EV to free cash flow | -45.5 | 0 | -13.28 | -6.28 | -5.87 | |
| Earnings yield | -0.02 | -0.02 | -0.05 | -0.13 | -0.15 | |
| Free cash flow yield | -0.02 | 0 | -0.05 | -0.13 | -0.15 | |
| Debt to equity | 0.05 | 0.06 | 0.08 | 0.25 | 0.26 | |
| Debt to assets | 0.05 | 0.05 | 0.07 | 0.2 | 0.21 | |
| Net debt to EBITDA | 13.44 | 9.77 | 8.29 | 1.56 | 0.81 | |
| Current ratio | 60.8 | 51.57 | 35.87 | 20.18 | 19.01 | |
| Interest coverage | -74.62 | -102.46 | -155.07 | -117.03 | -92.72 | |
| Income quality | 0.62 | 0 | 0.9 | 0.92 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 14.07 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.15 | 0 | 0.05 | 0.05 | 0.09 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -2.38 | |
| Capex to depreciation | -5.35 | 0 | -0.85 | -0.68 | -1.06 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 4.05 | |
| Graham number | 5.21 | 5.36 | 5.58 | 5.41 | 4.94 | |
| ROIC | 0.16 | 0.4 | 0.57 | -0.16 | -0.13 | |
| Return on tangible assets | -0.05 | -0.06 | -0.06 | -0.07 | -0.06 | |
| Graham Net | 4.72 | 4.43 | 4.15 | 2.87 | 2.62 | |
| Working capital | 358.24M | 341.02M | 316.71M | 271.94M | 254.31M | |
| Tangible asset value | 352.07M | 336.17M | 317.48M | 276.93M | 260.32M | |
| Net current asset value | 345.46M | 328.29M | 301.16M | 217.56M | 200.78M | |
| Invested capital | 0.03 | 0.03 | 0.05 | 0.21 | 0.23 | |
| Average receivables | 0 | 0 | 347K | 0 | 891K | |
| Average payables | 2.54M | 2.37M | 2.94M | 0 | 3.04M | |
| Average inventory | 0 | 0 | 3.16M | 0 | 17.46M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 107.41 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 353.5 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 2.08K | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0.84 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0.25 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0.04 | |
| ROE | -0.05 | -0.06 | -0.07 | -0.09 | -0.08 | |
| Capex per share | -0.02 | 0 | -0.01 | -0.02 | -0.03 |
OMIC Frequently Asked Questions
What is Singular Genomics Systems, Inc. stock symbol ?
Singular Genomics Systems, Inc. is a US stock , located in La jolla of Ca and trading under the symbol OMIC
What is Singular Genomics Systems, Inc. stock quote today ?
Singular Genomics Systems, Inc. stock price is $1.21 today.
Is Singular Genomics Systems, Inc. stock public?
Yes, Singular Genomics Systems, Inc. is a publicly traded company.
Company Profile
- Volume Average 136.91K
- Market Capitalization 87.05M
- Employee 269
- CEO Mr. Andrew Spaventa
- Headquarters La Jolla,CA,US
- IPO Date 2021-05-27
-
Website
https://singulargenomics.com 
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
